参考文献:Dongfeng Feng,et al., Excellent Response to Atezolizumab After Clinically Defined Hyperprogression Upon Previous Treatment With Pembrolizumab in Metastatic Triple-Negative Breast Cancer: A Case Report and Review of the Literature,Frontiers in Immunology,May 2021...
Journal of Experimental & Clinical Cancer ResearchHuang X, Xie X, Wang H, Xiao X, Yang L, Tian Z, Guo X, Zhang L, Tang H, Xie X. PDL1 And LDHA act as ceRNAs in triple negative breast cancer by regulating miR-34a. J Exp Clin Cancer Res. 2017;36:129.Huang, X., Xie, X., ...
1.LafonM,BlayeC,KindM,etal,Sarcoidosis‐likereactioninmetastatictriplenegativebreastcancertreatedbyanti‐PD‐L1.BreastJ.2019;00:1–3.
Triplenegative breast cancer (TNBC) is a subtype of breast cancer that is negative for oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 expression. Locally advanced and metastatic TNBC not only have a worse prognosis and are more invasive than TNBC, but are ...
[1] Jia H, Truica C I, Wang B, et al. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects[J]. Drug Resistance Updates, 2017, 32: 1-15. [2]Qingsong Huet al.Oncogenic lncR...
2024年1月6日,南丹麦大学分子医学研究所Henrik J.Ditzel教授团队在Molecular Cancer上发表题为: Adoptive cell transfer therapy with ex vivo primed peripheral lymphocytes in combination with anti‑PDL1 therapy effectively inhibits triple‑negative breast cancer growth and metastasis的研究性论文。
[14]Schmid, Peter, et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled...
Background: Triple-negative breast cancer(TNBC) has the highest recurrence and distant metastasis rates among breast cancer molecular types. In breast-conserving surgery, the insensitivity discrimination of negative margins correlating with locoregional recurrence and poor patient outcomes. As for ...
et al. Atezolizumab and Nab-paclitaxel in advanced triple-negative breast cancer. N. Engl. J. Med. 379, 2108–2121 (2018). CAS PubMed Google Scholar Latchman, Y. et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat. Immunol. 2, 261–268 (2001). CAS ...
This is a prospective, open-label, multicenter Phase II study evaluating the efficacy and safety of of SHR-A2102 in combination with Adebrelimab in Early Triple-Negative Breast Cancer(TNBC) 开始日期2025-03-01 申办/合作机构 河南省肿瘤医院 ...